Background:Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease due to the lack of specific early diagnostic markers. To improve the outcomes, proteomic approaches are being developed for the discovery of novel biomarkers of PDAC.Methods:Using tandem mass tag labelling and LC-MS/MS, we performed comparative analyses of pre- and postoperative sera from PDAC patients to identify specific serum biomarkers for PDAC. In validation studies, we evaluated the discriminatory power of candidate proteins.Results:Among the 302 proteins analysed, 20 were identified as potential biomarkers, with C4b-binding protein α-chain (C4BPA) and polymeric immunoglobulin receptor (PIGR) being selected for further analysis. The sera levels of C4BPA and PIGR were significantly higher in the preoperative PDAC patients than in the postoperative ones (P<0.008, P<0.036, respectively). In addition, serum C4BPA levels, but not PIGR, in patients with PDAC were significantly higher than those in healthy controls as well as in patients with pancreatitis and other malignancies including biliary tract cancers (BTC) (P<0.001). The respective area under the receiver operator characteristics (ROC) curve (AUC) was 0.860 for C4BPA, 0.846 for CA19-9 and 0.930 for the combination of C4BPA and CA19-9 in PDAC vs non-cancer individuals. The respective AUC was 0.912 for C4BPA, 0.737 for CA19-9 in Stages I and II of PDAC, 0.854 for C4BPA and 0.264 for CA19-9 in PDAC vs BTC.Conclusions:We have demonstrated that C4BPA is a novel serum biomarker for detecting early stage PDAC, as well as for distinguishing PDAC from other gastroenterological cancers. Further analysis in large cohort studies will warrant C4BPA as a promising biomarker of PDAC in clinical use.
One possible factor determining recovery of trace amount of protein biomarker
candidates during proteome analyses could be adsorption on urine tubes. This
issue, however, has not been well addressed so far. Recently, a new technical
device of surface coating by poly(2-methacryloyloxyethyl phosphorylcholine
(MPC)-co-n-butyl methacrylate (BMA))
(poly(MPC-co-BMA)) has been developed mainly to prevent the
adsorption of plasma proteins. We assessed whether conventionally used urine
tubes adsorb trace amount of urinary proteins and, if any, whether the surface
coating by poly(MPC-co-BMA) can minimize the adsorption.
Proteinuric urine samples were kept in poly(MPC-co-BMA)-coated
and noncoated urine tubes for 15 min and possibly adsorbed proteins and/or
peptides onto urine tubes were analyzed by SDS-PAGE, 2-DE, and the MALDI-TOF MS.
It was found that a number of proteins and/or peptides adsorb on the
conventionally used urine tubes and that surface coating by
poly(MPC-co-BMA) can minimize the adsorption without any
significant effects on routine urinalysis test results. Although it remains to
be clarified to what extent the protein adsorption can modify the results of
urinary proteome analyses, one has to consider this possible adsorption of
urinary proteins when searching for trace amounts of protein biomarkers in
urine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.